Article
Compensatory role of double mutation N348I/M184V on nevirapine binding landscape: insight from molecular dynamics simulation.
The protein journal - 1 Oct 2014
Karubiu Wilson, Bhakat Soumendranath, Soliman Mahmoud E S
Abstract excerpt
Non-nucleoside reverse transcriptase inhibitors (NNRTI) have emerged as gold standards in current anti-AIDS drug discovery and development by allosterically inhibiting HIV reverse transcriptase (HIV-RT). Connection sub-domain mutation, N348I and the M184V active site mutation decreases HIV-1 RT susceptibility to NNRTI, nevirapine (NVP), whereas concurrence of both mutations improves enzyme susceptibility to NVP....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
